Artemis Medicare Services Ltd
Fundamental Score
Artemis Medicare Services Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of ARTEMISMED across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Robust Profit Growth (32.80%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Excellent EPS Growth (31.44% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (32.46% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Strong Interest Coverage (5.31x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹33.75 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (58.43%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Risk Factors
3 factors identified
Premium Valuation Risk (P/E: 46.29x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
High Share Pledging Risk (44.53%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns or margin calls.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Financial Statements
Comprehensive financial data for Artemis Medicare Services Ltd
About ARTEMISMED
Business Overview
Artemis Medicare Services Limited engages in the management and operation of multi-specialty hospitals in India and internationally. The company provides medical and surgical intervention, and inpatient and outpatient services. It also offers billing and insurance, childcare, emotional and support program, full body checkup, international patient, medical interpreter and record, mind body medicine, nursing, nutrition, patient and family advisory, patient advocacy and portal, pre-admission testing, and smoking cessation program services, as well as home care services. Artemis Medicare Services Limited was incorporated in 2004 and is based in Gurugram, India.
Company Details
Key Leadership
Corporate Events
ARTEMISMED Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Artemis Medicare Services Ltd (ARTEMISMED)?
As of 21 Jan 2026, 08:47 am IST, Artemis Medicare Services Ltd (ARTEMISMED) is currently trading at ₹235.30. The stock has a market capitalization of ₹4.41K (Cr).
Is ARTEMISMED share price Overvalued or Undervalued?
ARTEMISMED is currently trading at a P/E ratio of 46.29x, compared to the industry average of 52.84x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Artemis Medicare Services Ltd share price?
Key factors influencing ARTEMISMED's price include its quarterly earnings growth (Sales Growth: 14.96%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Artemis Medicare Services Ltd a good stock for long-term investment?
Artemis Medicare Services Ltd shows a 5-year Profit Growth of 32.46% and an ROE of 12.92%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.31 before investing.
How does Artemis Medicare Services Ltd compare with its industry peers?
Artemis Medicare Services Ltd competes with major peers in the Hospital. Investors should compare ARTEMISMED's P/E of 46.29x and ROE of 12.92% against the industry averages to determine its competitive standing.
What is the P/E ratio of ARTEMISMED and what does it mean?
ARTEMISMED has a P/E ratio of 46.29x compared to the industry average of 52.84x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹46 for every ₹1 of annual earnings.
How is ARTEMISMED performing according to Bull Run's analysis?
ARTEMISMED has a Bull Run fundamental score of 41/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does ARTEMISMED belong to?
ARTEMISMED operates in the Hospital industry. This classification helps understand the competitive landscape and sector-specific trends affecting Artemis Medicare Services Ltd.
What is Return on Equity (ROE) and why is it important for ARTEMISMED?
ARTEMISMED has an ROE of 12.92%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Artemis Medicare Services Ltd generates profits from shareholders' equity.
How is ARTEMISMED's debt-to-equity ratio and what does it indicate?
ARTEMISMED has a debt-to-equity ratio of 0.31, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.
What is ARTEMISMED's dividend yield and is it a good dividend stock?
ARTEMISMED offers a dividend yield of 0.16%, which means you receive ₹0.16 annual dividend for every ₹100 invested.
How has ARTEMISMED grown over the past 5 years?
ARTEMISMED has achieved 5-year growth rates of: Sales Growth 10.15%, Profit Growth 32.46%, and EPS Growth 31.44%.
What is the promoter holding in ARTEMISMED and why does it matter?
Promoters hold 58.43% of ARTEMISMED shares, with 44.53% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is ARTEMISMED's market capitalization category?
ARTEMISMED has a market capitalization of ₹4414 crores, placing it in the Small-cap category.
How volatile is ARTEMISMED stock?
ARTEMISMED has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for ARTEMISMED?
ARTEMISMED has a 52-week high of ₹N/A and low of ₹N/A.
What is ARTEMISMED's operating profit margin trend?
ARTEMISMED has a 5-year average Operating Profit Margin (OPM) of 13.90%, indicating the company's operational efficiency.
How is ARTEMISMED's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 14.96% and YoY Profit Growth of 32.80%.
What is the institutional holding pattern in ARTEMISMED?
ARTEMISMED has FII holding of 12.48% and DII holding of 3.35%. Significant institutional holding often suggests professional confidence in the stock.